摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

oxazolo<4,5-b>pyridin-2(3H)-one | 59851-50-2

中文名称
——
中文别名
——
英文名称
oxazolo<4,5-b>pyridin-2(3H)-one
英文别名
3H-oxazolo[4,5-c]pyridin-2-one;3H-Oxazolo[4,5-c]pyridin-2-on;Oxazolo[4,5-c]pyridin-2(3H)-one;3H-[1,3]oxazolo[4,5-c]pyridin-2-one
oxazolo<4,5-b>pyridin-2(3H)-one化学式
CAS
59851-50-2
化学式
C6H4N2O2
mdl
——
分子量
136.11
InChiKey
DCIHMFKXUPIFLL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    51.2
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:bf53061a59ba2f097591ec5073c89886
查看

反应信息

  • 作为反应物:
    描述:
    oxazolo<4,5-b>pyridin-2(3H)-one 生成 6-Bromooxooxazolo[4,5-c]pyridine
    参考文献:
    名称:
    SPADA, ALFRED P.;STUDT, WILLIAM L.;CAMPBELL, HENRY F.;KUHLA, DONALD E.;TU+
    摘要:
    DOI:
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 180.0~210.0 ℃ 、333.31 Pa 条件下, 生成 oxazolo<4,5-b>pyridin-2(3H)-one
    参考文献:
    名称:
    Takahashi; Koshiro, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1959, vol. 79, p. 1123,1125
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1
    申请人:GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD
    公开号:WO2021004547A1
    公开(公告)日:2021-01-14
    This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)
    这项披露涉及杂环化合物作为HPK1的抑制剂,特别涉及公式I的化合物或其药用盐,以及包含该化合物的药物组合物,用于治疗HPK1介导的疾病和状况,如癌症。 (I)
  • ANTIVIRAL COMPOUNDS
    申请人:Alios BioPharma, Inc.
    公开号:US20160244460A1
    公开(公告)日:2016-08-25
    Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    本文披露了新的抗病毒化合物,以及包括一个或多个抗病毒化合物的药物组合物,以及合成这些化合物的方法。本文还披露了使用一个或多个小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒(RSV)引起的感染。
  • A New Synthesis of Cyclic Ureas, Cyclic Urethanes, and a Quinazolinedione. Selenium-Assisted Carbonylation of Aromatic Amines with Carbon Monoxide
    作者:Tohru Yoshida、Nobuaki Kambe、Shinji Murai、Noboru Sonoda
    DOI:10.1246/bcsj.60.1793
    日期:1987.5
    Five-, six-, and seven-membered cyclic ureas were synthesized in excellent yields from various aromatic diamines by reaction with carbon monoxide and a stoichiometric or excess amount of selenium i...
    通过与一氧化碳和化学计量或过量的硒反应,从各种芳族二胺中以优异的收率合成了五元​​、六元和七元环脲。
  • ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE
    申请人:Shionogi & Co., Ltd.
    公开号:US20140288302A1
    公开(公告)日:2014-09-25
    A pharmaceutical composition including a compound of formula (I): its pharmaceutically acceptable salt, or a solvate thereof. Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by formula: —C(R 1 R 2 )—C(═O)—NR 3 R 4 and a group represented by formula: —R 5 , a broken line represents presence or absence of a bond, Z is —NR 6 —, ═N—, —O—, or —S—, R 6 is halogen or substituted or unsubstituted alkyl, R 1 and R 2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is hydrogen or substituted or unsubstituted alkyl, R 3 and R 4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R 5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl.
    一种包括化合物(I)的制药组合物:其药学上可接受的盐或其溶剂合物。环A是含氮杂环,环A可以用除了公式所表示的基团之外的取代基团取代:—C(R1R2)—C(═O)—NR3R4和公式表示的基团:—R5,其中断线表示键的存在或不存在,Z是—NR6—,═N—,—O—或—S—,R6是卤素或取代或未取代的烷基,R1和R2各自独立地是氢、卤素、羟基、氰基、硝基、羧基或取代或未取代的烷基,R3是氢或取代或未取代的烷基,R4是氢或取代或未取代的烷基,R3和R4与它们所连接的相邻氮原子一起可以形成取代或未取代的环,R5是氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基或取代或未取代的炔基。
  • Antiviral compounds
    申请人:Alios BioPharma, Inc.
    公开号:US10358453B2
    公开(公告)日:2019-07-23
    Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    本文公开了新的抗病毒化合物,以及包括一种或多种抗病毒化合物的药物组合物和合成这些化合物的方法。本文还公开了用一种或多种小分子化合物改善和/或治疗副黏液病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒(RSV)引起的感染。
查看更多

同类化合物

甲基吡噁磷 甲基吡啶磷-d6 恶唑并[5,4-B]吡啶-2-胺二盐酸盐 恶唑并[5,4-B]吡啶-2-胺 恶唑并[5,4-B]吡啶-2(1H)-硫酮 恶唑并[4,5-B]吡啶-2(3H)硫酮 噁唑并[5,4-c]吡啶-2-胺 噁唑并[5,4-c]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶 噁唑并[4,5-c]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-羧酸乙酯 噁唑并[4,5-b]吡啶-2(3H)-酮,6-溴-3-(苯基甲基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,6-乙酰基-3-[2-(2-吡啶基)乙基]- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-羰基丙基)- 噁唑并[4,5-b]吡啶,2-(1-甲基乙基)-(9CI) 噁唑并[4,5-b]吡啶 噁唑并[4,5-C]吡啶-2(3H)-硫酮 噁唑并[4,5-C]吡啶 [1,3]恶唑并[4,5-c]吡啶-6-羧酸 7-溴恶唑并[4,5-C]吡啶 7-溴-2-甲基-F唑并[4,5-C]吡啶 7-溴-2-乙基恶唑并[4,5-C]吡啶 6-溴恶唑并[5,4-B]吡啶-2-胺 6-溴恶唑并[5,4-B]吡啶 6-溴噁唑并[4,5-b]吡啶 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 6-溴-2-甲基噁唑并[5,4-b]吡啶 6-溴-2-甲基噁唑并[4,5-B]吡啶 6-溴-2-(三氟甲基)噁唑并[5,4-B]吡啶 6-溴-2-(三氟甲基)噁唑并[4,5-b]吡啶 6-氯恶唑并[4,5-b]吡啶-2(3H)-酮 5-甲基噁唑并[4,5-b]吡啶-2(3h)-酮 5-甲基-3H-恶唑并[4,5-B]吡啶-2-硫酮 5-溴-3H-恶唑并[4,5-b]吡啶-2-酮 3-[2-(4-氯苯基)乙基]-2-苯基亚氨基-1,3-噻唑烷-4-酮 3-(2-溴乙基)恶唑并[4,5-b]吡啶-2(3H)-酮 3-(2-吗啉-4-基乙基)[1,3]噁唑并[4,5-b]吡啶-2(3H)-酮 2-甲硫基唑并[4,5-B]吡啶 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 2-甲基噁唑并[5,4-c]吡啶 2-甲基噁唑并[5,4-b]吡啶 2-甲基吡啶并噁唑 2-甲基[1,3]噁唑并[4,5-b]吡啶 2-氯甲基噁唑并[4,5-b]吡啶 2-氯恶唑并[5,4-b]吡啶 2-氯恶唑并[5,4-C]吡啶盐酸盐 2-氯恶唑并[5,4-C]吡啶 2-氯噁唑并[4,5-B]吡啶